Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

WIN Trial

Trial Name

WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.


The WIN trisl studys the effect of DNA vaccination with two DNA vaccines, p.DOM-WT1-37 and p.DOM-WT1 in two patient groups Chronic Myeloid Leukaemia (CML) and Acute Myeloid Leukaemia (AML).


Primary Objectives:

Secondary Objectives:


Open label, single dose level, Phase II study in two patient groups (CML and AML) using genetic randomisation. Consented and eligible HLA A2+ve patients will be vaccinated with two DNA vaccines. HLA A2 –ve patients will be followed up on trial without vaccination. 




Contact Details

All Trial enquiries should be addressed to

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.